Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (131)	2/9/1999 9:19:00 AM
From: MarcG	Respond to of 370

Thanks Jim. That VION summary of the TAPET technology spells out the objectives. Here it is again: Message 7023405

To: Jim Oravetz who wrote (131)	2/9/1999 10:10:00 AM
From: scaram(o)uche	Respond to of 370

Jim: I read the manuscript. I need more info. It looks as though the bug still makes lipid A, but produces it at a markedly reduced level. If the bug produces 1% of the normal levels of lipid A, it doesn't take many divisions until you have the same level of endotoxin. Not certain that FDA will buy into clinical testing. One spends a lot of time trying to prevent chemotherapy patients from getting Gram-negatives. Good stuff, just not certain that it's practical. Rick

To: Jim Oravetz who wrote (131)	3/18/1999 1:11:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 370

March 18, 1999 Dow Jones Newswires Vion Pharma Files Investigational NDA For Vector Study Dow Jones Newswires NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) filed an investigational new drug application with the Food and Drug Administration to conduct a safety trial for its Tapet vector to treat solid tumors. In a press release Thursday, Vion said the Phase I trial will investigate human clinical safety of intratumoral injections of the Tapet vectors in patients with solid tumors. The company said Tapet vectors are Salmonella bacteria that have been genetically engineered for safety and to preferentially target solid tumors over normal tissues to treat cancer. Preclinical studies indicate Tapet vectors were safe and able to suppress tumor growth in various animal models, the company said. Vion Pharmaceuticals is a biopharmaceutical company that develops and commercializes products to treat cancer and viral diseases.